NCT04142554View on ClinicalTrials.gov

Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 1, 2020

Primary Completion Date

September 7, 2020

Study Completion Date

September 7, 2020

Conditions

Breast CancerBreast NeoplasmsTriple Negative Breast CancerHER2-positive Breast Cancer

Interventions

DRUG

Parsaclisib

Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER